Clinical Trials
10 trialsNCT00861510 2019-12-03
A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00854646 2018-01-10
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
Traws Pharma, Inc.
Phase 1 Completed
NCT00861328 2017-06-23
Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin
Traws Pharma, Inc.
Phase 1 Completed
NCT00861783 2017-06-23
Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma
Traws Pharma, Inc.
Phase 1 Completed
NCT01125891 2017-06-23
Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
Traws Pharma, Inc.
Phase 1 Completed
NCT01165905 2017-06-23
Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors
Traws Pharma, Inc.
Phase 1 Completed
NCT01168011 2017-06-23
Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors
Traws Pharma, Inc.
Phase 1 Completed
NCT01538537 2017-06-23
Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer
Traws Pharma, Inc.
Phase 1 Completed
NCT01538563 2017-06-23
Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer
Traws Pharma, Inc.
Phase 1 Completed
NCT02107235 2017-06-23
Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer
Traws Pharma, Inc.
Phase 1 Completed